Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination StrategiesJennifer O'Neil, Yair Benita, Igor Feldman, et al.
BMC Medical Genomics|July 2, 2010
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumorsAndrey Loboda, Michael Nebozhyn, Rich Klinghoffer, et al.
Nature Communications|June 16, 2016
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APCMichael J Schell, Mingli Yang, Jamie K Teer, et al.
The Journal of Clinical Investigation|June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Molecular Cancer Research : MCR|December 29, 2020
ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor CellsLatika Singh, Eric S Muise, Anannya Bhattacharya, et al.
Vaccine|October 16, 2012
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza VaccineEugene Maraskovsky, Steve Rockman, Allison Dyson, et al.
Oncotarget|October 24, 2018
Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1Robbie L McLeod, Minilik H Angagaw, Toya Nath Baral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
BMC Medical Genomics|February 11, 2009
Diurnal variation of the human adipose transcriptome and the link to metabolic diseaseAndrey Loboda, Walter K Kraft, Bernard Fine, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Pageof 7